%22%20d%3D%22M50.5%2036.41A25%2025%200%200%201%2036.41%2050.5L31.27%2037.48A11%2011%200%200%200%2037.48%2031.27Z%22%2F%3E%0A%3C%2Fsvg%3E){kind=small}
Revenue
$22.97B +47.7% on Q2 2025
NYSE:LLY
Eli Lilly KPIs
Eli Lilly had revenue of $23.0 billion in Q2 2026, the quarter that ended Jun 30, 2026, 48% more than a year earlier. Below are its quarterly and annual figures, split by region and product.
Latest quarter, Q2 2026 ended Jun 30, 2026
Revenue
$22.97B ▲
47.7%
Net income
$7.10B ▲
25.3%
Revenue by region
Q2 2026
- United States $14.4B
- Europe $4.12B
- Rest of world $2.88B
- Japan $628M
- China $941M
Revenue by product
Q2 2026
- Mounjaro $9.94B
- Trulicity $1.22B
- Zepbound $4.93B
- Verzenio $1.47B
- Jardiance $1.23B
- Taltz $856M
- Other (23) $3.32B
Margins
Q2 2026
Net income
$7.10B +25.3% on Q2 2025
Eli Lilly's figures by quarter
Revenue
| Eli Lilly revenue by quarter | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | $22.97B | $19.80B | $19.29B | $17.60B | $15.56B | $12.73B | $13.53B | $11.44B | $11.30B | $8.77B | $9.35B | $9.50B | $8.31B | $6.96B | $7.30B | $6.94B | $6.49B | $7.81B | $8.00B | $6.77B |
| Regions | ||||||||||||||||||||
| United States | $14.41B | $12.12B | $12.88B | $11.30B | $10.81B | $8.49B | $9.03B | $7.81B | $7.84B | $5.69B | $6.46B | $5.37B | $5.53B | $4.44B | $4.66B | $4.42B | $3.93B | $5.17B | $5.18B | $3.99B |
| Europe | $4.12B | $3.65B | $3.10B | $3.50B | $2.57B | $2.39B | $2.45B | $1.63B | $1.40B | $1.44B | $1.34B | $2.57B | $1.18B | $1.09B | $1.07B | $1.06B | $1.10B | $1.07B | $1.15B | $1.10B |
| Rest of world | $2.88B | $2.77B | $2.19B | $1.69B | $1.18B | $997.00M | $1.06B | $1.11B | $1.21B | $892.90M | $744.40M | $780.30M | $748.50M | $673.10M | $822.90M | $632.00M | $645.70M | $751.50M | $765.50M | $689.40M |
| China | $941.00M | $693.00M | $473.20M | $560.40M | $466.00M | $451.00M | $429.20M | $459.90M | $395.10M | $376.20M | $377.10M | $390.80M | $399.00M | $372.70M | $350.80M | $343.40M | $352.10M | $406.50M | $376.40M | $400.30M |
| Japan | $628.00M | $571.00M | $654.80M | $554.70M | $521.00M | $402.00M | $559.20M | $429.10M | $462.70M | $363.90M | $439.00M | $390.80M | $455.60M | $387.20M | $395.00M | $487.70M | $454.40M | $410.20M | $534.80M | $595.00M |
| Products | ||||||||||||||||||||
| Mounjaro | $9.94B | $8.66B | $6.52B | $5.20B | $3.84B | $3.11B | $3.09B | $1.81B | $1.41B | $979.70M | $568.50M | $187.30M | $16.00M | $0.00 | $0.00 | |||||
| Zepbound | $4.93B | $4.16B | $3.59B | $3.38B | $2.31B | $1.26B | $1.24B | $517.40M | $0.00 | $0.00 | $0.00 | |||||||||
| Zyprexa | $1.48B | $81.40M | ||||||||||||||||||
| Verzenio | $1.47B | $1.30B | $1.47B | $1.49B | $1.16B | $1.37B | $1.33B | $1.05B | $1.04B | $926.80M | $750.90M | $617.70M | $588.50M | $469.40M | $335.50M | |||||
| Jardiance | $1.23B | $1.11B | $768.60M | $959.00M | $690.00M | $1.01B | $1.20B | $686.40M | $769.60M | $686.50M | $798.10M | $700.80M | $668.30M | $577.50M | $612.30M | $573.30M | $461.00M | $419.40M | $431.90M | $390.40M |
| Trulicity | $1.22B | $919.00M | $1.05B | $1.09B | $1.10B | $1.30B | $1.25B | $1.46B | $1.67B | $1.81B | $1.98B | $1.85B | $1.91B | $1.74B | $1.60B | |||||
| Other oncology | $1.10B | $966.00M | $937.40M | $924.00M | $789.00M | $862.50M | $826.80M | $759.70M | $213.80M | $217.80M | $177.40M | $179.20M | $180.40M | $186.70M | $100.30M | |||||
| Other cardiometabolic health | $1.03B | $905.00M | $1.06B | $980.00M | $945.00M | $1.05B | $1.17B | $1.03B | $141.90M | $136.60M | $130.40M | $125.00M | $144.60M | $177.40M | ||||||
| Taltz | $856.00M | $733.00M | $901.50M | $848.00M | $762.00M | $879.60M | $824.70M | $604.10M | $744.20M | $703.90M | $527.00M | $679.90M | $606.20M | $488.10M | $593.10M | |||||
| Other immunology | $561.00M | $470.00M | $460.90M | $408.00M | $326.00M | $306.10M | $257.70M | $229.90M | $11.40M | $5.70M | $22.00M | $3.60M | $4.00M | $4.50M | $4.90M | |||||
| Neuroscience | $429.00M | $382.00M | $315.70M | $344.00M | $272.00M | $351.80M | $339.50M | $389.10M | $1.77B | $387.20M | $360.50M | $373.20M | $389.90M | $397.70M | $450.20M | |||||
| Humalog® | $395.40M | $440.40M | $460.90M | $447.00M | $447.10M | $618.20M | $626.70M | |||||||||||||
| Other Product Total | $337.20M | $262.80M | $207.60M | $241.90M | $276.10M | $314.60M | $275.30M | $746.00M | $494.70M | $1.92B | $637.70M | |||||||||
| Olumiant | $231.40M | $218.90M | $228.90M | $205.80M | $182.90M | $186.20M | $255.60M | $306.00M | $406.90M | |||||||||||
| Cyramza® | $224.10M | $260.30M | $236.80M | $232.10M | $231.30M | $230.30M | $253.40M | |||||||||||||
| Humulin® | $206.70M | $205.30M | $252.00M | $238.20M | $274.00M | $273.20M | $286.70M | |||||||||||||
| Other Product | $205.00M | $187.00M | $202.00M | $213.00M | $42.90M | $51.00M | $52.80M | $66.60M | $80.10M | $98.10M | ||||||||||
| Basaglar® | $179.60M | $154.20M | $209.30M | $201.70M | $193.00M | $174.20M | $191.50M | $242.40M | $192.80M | |||||||||||
| Emgality® | $168.50M | $168.50M | ||||||||||||||||||
| Erbitux® | $153.90M | $162.50M | $129.90M | $144.90M | $140.80M | $122.70M | $134.30M | |||||||||||||
| Forteo® | $146.40M | $148.00M | $122.30M | $177.10M | $138.50M | $137.40M | ||||||||||||||
| Other diabetes and obesity | $145.10M | |||||||||||||||||||
| Alimta® | $119.40M | $227.70M | $343.90M | $457.00M | ||||||||||||||||
| Other neuroscience | $118.20M | $123.30M | ||||||||||||||||||
| Tyvyt | $115.10M | $103.60M | $61.00M | $77.90M | $125.60M | |||||||||||||||
| Trajenta (BI) | $95.20M | $103.60M | $85.80M | $90.70M | $103.80M | $97.10M | $92.00M | $92.60M | ||||||||||||
| Cialis® | $86.80M | $115.60M | $100.30M | $115.70M | $147.00M | $217.70M | ||||||||||||||
| Collaboration and other revenue associated with prior period transfers of intellectual property | $32.50M | $43.30M | $34.40M | $53.20M | $38.90M | |||||||||||||||
| Baqsimi | $13.10M | $613.90M | $43.00M | $29.00M | ||||||||||||||||
Net income
| Eli Lilly net income by quarter | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | $7.10B | $7.40B | $6.64B | $5.58B | $5.66B | $2.76B | $4.41B | $970.30M | $2.97B | $2.24B | $2.19B | −$57.40M | $1.76B | $1.34B | $1.94B | $1.45B | $952.50M | $1.90B | $1.73B | $1.11B |
Eli Lilly's latest quarter
Revenue was $23.0 billion and net income was $7.1 billion. That's a net margin of 30.9%.
By region, United States brought in the most, 63% of the total.
Eli Lilly's fiscal year
Eli Lilly reports on the calendar year, so 2025 ended on Dec 31, 2025 and its quarters line up with the calendar's.
Get Eli Lilly's KPIs from the API
/v1/kpis returns the same series as this page. Send it up to 100 symbols at once, pick quarterly, half
year or annual periods, and narrow it to the KPIs you need.
GET
/v1/kpis 2 credits per instrument curl "https://api.quova.io/v1/kpis?symbols=NYSE:LLY" \
-H "Authorization: Bearer $QUOVA_API_KEY"Questions
How up to date is it?
Each page is built with the figures we had when it was published, then checks for newer ones every time it's opened. A new quarter shows up here soon after Eli Lilly reports it.
Can I get these figures in my own code?
Yes. GET /v1/kpis returns the same series as JSON or CSV, for other US companies as well as these. Some companies have KPIs of their own there too, like trips at Uber. It works over REST, or from an AI assistant through our MCP server.
What does the API cost?
2 credits per instrument. It's included in every paid plan, and in the trial. Anything that comes back as an error isn't billed.
Related
Browse other companies
- Nvidia KPIs Revenue of $96.22B in Q2 FY2027, up 105.9% on a year before.
- Apple KPIs Revenue of $109.42B in Q3 FY2026, up 16.4% on a year before.
- Alphabet KPIs Revenue of $119.80B in Q2 2026, up 24.2% on a year before.
- Microsoft KPIs Revenue of $92.28B in Q1 FY2027, up 18.8% on a year before.
- Amazon KPIs Revenue of $200.61B in Q2 2026, up 19.6% on a year before.
- Broadcom KPIs Revenue of $29.59B in Q3 FY2026, up 85.5% on a year before.
- Tesla KPIs Revenue of $28.05B in Q3 2026, down 0.2% on a year before.
- Meta KPIs Revenue of $64.60B in Q3 2026, up 26.1% on a year before.
- Berkshire Hathaway KPIs Revenue of $101.81B in Q2 2026, up 10.0% on a year before.
- Micron KPIs Revenue of $54.23B in Q4 FY2026, up 379.3% on a year before.
- AMD KPIs Revenue of $11.54B in Q2 2026, up 50.1% on a year before.
- Walmart KPIs Revenue of $187.94B in Q2 FY2027, up 5.9% on a year before.
- JPMorgan Chase KPIs Revenue of $57.35B in Q2 2026, up 27.7% on a year before.
- Visa KPIs Revenue of $11.63B in Q3 FY2026, up 14.4% on a year before.
- ExxonMobil KPIs Revenue of $116.02B in Q2 2026, up 42.3% on a year before.
- Johnson & Johnson KPIs Revenue of $25.40B in Q3 2026, up 5.9% on a year before.
- Mastercard KPIs Revenue of $9.28B in Q2 2026, up 14.1% on a year before.
- AbbVie KPIs Revenue of $16.99B in Q2 2026, up 10.2% on a year before.
- Intel KPIs Revenue of $16.13B in Q2 2026, up 25.4% on a year before.
- Palantir KPIs Revenue of $1.94B in Q2 2026, up 92.8% on a year before.
- Chevron KPIs Revenue of $70.06B in Q2 2026, up 56.3% on a year before.
- Cisco KPIs Revenue of $17.25B in Q4 FY2026, up 17.6% on a year before.
- Costco KPIs Revenue of $95.72B in Q4 FY2026, up 11.1% on a year before.
- Oracle KPIs Revenue of $19.35B in Q1 FY2027, up 29.6% on a year before.
- Coca-Cola KPIs Revenue of $13.38B in Q3 2026, up 7.4% on a year before.
- Procter & Gamble KPIs Revenue of $23.28B in Q1 FY2027, up 4.0% on a year before.
- UnitedHealth KPIs Revenue of $112.03B in Q2 2026, up 0.4% on a year before.
- Bank of America KPIs Revenue of $31.56B in Q2 2026, up 15.0% on a year before.
- Merck KPIs Revenue of $16.61B in Q2 2026, up 5.1% on a year before.
- Palo Alto Networks KPIs Revenue of $3.41B in Q4 FY2026, up 34.5% on a year before.
- Caterpillar KPIs Revenue of $20.54B in Q2 2026, up 24.0% on a year before.
- Home Depot KPIs Revenue of $47.86B in Q2 FY2027, up 5.7% on a year before.
- Philip Morris KPIs Revenue of $11.44B in Q3 2026, up 5.5% on a year before.
- Applied Materials KPIs Revenue of $9.12B in Q3 FY2026, up 24.8% on a year before.
- GE Aerospace KPIs Revenue of $14.12B in Q3 2026, up 15.9% on a year before.
- Lam Research KPIs Revenue of $8.22B in Q1 FY2027, up 54.4% on a year before.
- Morgan Stanley KPIs Revenue of $21.35B in Q2 2026, up 27.1% on a year before.
- Texas Instruments KPIs Revenue of $6.06B in Q3 2026, up 27.7% on a year before.
- CrowdStrike KPIs Revenue of $1.47B in Q2 FY2027, up 25.8% on a year before.
- Goldman Sachs KPIs Revenue of $20.34B in Q2 2026, up 39.5% on a year before.
- RTX KPIs Revenue of $24.97B in Q3 2026, up 11.1% on a year before.
- Netflix KPIs Revenue of $12.87B in Q3 2026, up 11.8% on a year before.
- Thermo Fisher KPIs Revenue of $11.99B in Q2 2026, up 10.5% on a year before.
- Wells Fargo KPIs Revenue of $21.87B in Q3 2026, up 2.0% on a year before.
- Amgen KPIs Revenue of $10.05B in Q2 2026, up 9.5% on a year before.
- GE Vernova KPIs Revenue of $12.64B in Q3 2026, up 26.8% on a year before.
- IBM KPIs Revenue of $17.10B in Q3 2026, up 4.7% on a year before.
- Arista Networks KPIs Revenue of $3.04B in Q2 2026, up 37.7% on a year before.
- Linde KPIs Revenue of $9.29B in Q2 2026, up 9.3% on a year before.
Try every endpoint for 14 days
The trial has 5,000 credits and full API access, and you don't need a card for it. After that paid plans start at $29 a month, and there's a free plan for personal projects.